Randomized trial secondary analysis reveals synergistic kidney benefits from combined exenatide and dapagliflozin in obese type 2 diabetes, suggesting enhanced dual renal protection.
This prespecified secondary analysis suggests that combined therapy with exenatide and dapagliflozin may have synergistic effects on markers of kidney function compared to either therapy alone or placebo in obese patients with type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
Ruiten et al. (2021) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: